Funding for this research was provided by:
Aichi Cancer Research Foundation (2021-1-19)
National Cancer Research and Development (2021-A-11)
Article History
Received: 18 March 2022
Revised: 21 April 2022
Accepted: 21 April 2022
First Online: 9 May 2022
Declarations
:
: YM received honoraria from Bristol-Myers Squibb, Novartis, and Pfizer. MY received research funding from AbbVie and Novartis; and honoraria from AbbVie, Daiichi Sankyo, and Kyowa Kirin.